A total of 29 companies entered the public market this past week, the most ever in a single week. The week’s 11 IPOs were joined by 15 SPACs and three direct listings. Notable new IPO filings included TPG-backed antivirus provider ...read more
Immunome, a preclinical biotech developing antibody therapies for cancer and infectious diseases, raised $39 million by offering 3.3 million shares at $12, within the range of $11 to $13. The company offered 0.8 million more shares than anticipated. At pricing,...read more
Updated Monday, 9/28.
11 IPOs and two direct listings are scheduled to go public in the week ahead. The diverse group includes three foreign tech issuers, two biotechs, two US tech unicorns, a sporting goods retailer, an avocado supplier, a medical...read more
Immunome, a preclinical biotech developing antibody therapies for cancer and infectious diseases, announced terms for its IPO on Thursday. The Exton, PA-based company plans to raise $30 million by offering 2.5 million shares at a price range of $11 to $13....read more
US IPO Weekly Recap: IPOs, SPACs, and direct listings, oh my!
A total of 29 companies entered the public market this past week, the most ever in a single week. The week’s 11 IPOs were joined by 15 SPACs and three direct listings. Notable new IPO filings included TPG-backed antivirus provider ...read more
Preclinical oncology biotech Immunome prices upsized IPO at $12 midpoint
Immunome, a preclinical biotech developing antibody therapies for cancer and infectious diseases, raised $39 million by offering 3.3 million shares at $12, within the range of $11 to $13. The company offered 0.8 million more shares than anticipated. At pricing,...read more
US IPO Week Ahead: Palantir and Asana direct-list in 11 IPO week with tech, sports, and avocados
Updated Monday, 9/28. 11 IPOs and two direct listings are scheduled to go public in the week ahead. The diverse group includes three foreign tech issuers, two biotechs, two US tech unicorns, a sporting goods retailer, an avocado supplier, a medical...read more
Preclinical oncology biotech Immunome sets terms for $30 million IPO
Immunome, a preclinical biotech developing antibody therapies for cancer and infectious diseases, announced terms for its IPO on Thursday. The Exton, PA-based company plans to raise $30 million by offering 2.5 million shares at a price range of $11 to $13....read more